The Top Line cover image

AbbVie, ADCs and the future of cancer care

The Top Line

00:00

Advancements in Targeting CMET Overexpression in Cancer Treatment

This chapter explores a breakthrough in cancer treatment through the use of TMAPA, a second-generation antibody-drug conjugate targeting CMET overexpression. It highlights encouraging clinical data demonstrating high response rates in patients with non-small cell lung and colorectal cancers, emphasizing its potential to enhance outcomes in challenging cases.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app